qs_id,statement_number,statement
QS41,1,Adults with a baseline total cholesterol above 7.5 mmol/l are assessed for a clinical diagnosis of familial hypercholesterolaemia (FH).
QS41,2,People with a clinical diagnosis of familial hypercholesterolaemia (FH) are referred for specialist assessment.
QS41,3,People with a clinical diagnosis of familial hypercholesterolaemia (FH) are offered DNA testing as part of a specialist assessment.
QS41,4,Children at risk of familial hypercholesterolaemia (FH) are offered diagnostic tests by the age of 10 years.
QS41,5,"Relatives of people with a confirmed diagnosis of monogenic familial hypercholesterolaemia (FH) are offered DNA testing through a nationwide, systematic cascade process."
QS41,6,Adults with familial hypercholesterolaemia (FH) receive lipid‑modifying drug treatment to reduce LDL‑C concentration by more than 50% from baseline.
QS41,7,Children with familial hypercholesterolaemia (FH) are assessed for lipid‑modifying drug treatment by a specialist with expertise in FH in a child‑focused setting by the age of 10 years.
QS41,8,People with familial hypercholesterolaemia (FH) are offered a structured review at least annually.
